Overview

Berry Genomics recently announced that it will acquire NeoGenomics, a US-based blood testing company, for US$2.4 billion to further strengthen its oncology testing business.

Berry Genomics’ oncology testing business

As a leading comprehensive genetic sequencing company in China, Berry Genomics has developed a full range of genetic testing services with oncology testing as the core. Its tumor testing covers dozens of common cancers such as lung cancer, breast cancer, stomach cancer, liver cancer and ovarian cancer, and provides precise and personalized treatment as well.

The significance of the acquisition

NeoGenomics is a leading US-based blood tumor testing company, whose tests are widely used in the diagnosis, treatment and monitoring of tumors. The acquisition will enable NeoGenomics to achieve comprehensive coverage in the field of oncology testing and further enhance its competitiveness in the international market.

Berry Genomics’ international development strategy

In recent years, Berry Genomics has also been rapidly expanding its presence in overseas markets. In addition to obtaining the CE mark for the world's first COVID-19 neuronal protein antibody test, Berry Genomics has also set up a number of laboratories and offices in Europe, Africa and Asia, and has strengthened its cooperation with large international hospitals, disease control centers and pharmaceutical companies. This acquisition is another important step in the implementation of Berry Genomics' internationalization strategy.

Summary

The acquisition of NeoGenomics will further strengthen Berry Genomics’ leading position in the oncology testing business, which has become its core competency. In the future, Berry Genomics will continue to innovate in genetic testing technology and make greater contributions to human health.